Development of Posterior Uveitis in Behçet Syndrome Patients with Vitreous Cells at Baseline


Uçar D., Bircan B. E., Rustamli N., Batu Oto B., Hamuryudan V., Hatemi G., ...Daha Fazla

Ocular Immunology and Inflammation, cilt.33, sa.2, ss.243-249, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/09273948.2024.2383315
  • Dergi Adı: Ocular Immunology and Inflammation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.243-249
  • Anahtar Kelimeler: Behçet syndrome, eye involvement, immunosuppressive, uveitis, vitreous cell
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Purpose: The prognostic importance of vitreous cells (VC) in patients with Behçet syndrome (BS) is unknown. We aimed to determine the frequency of developing posterior uveitis (PU) and any additional risk factors associated with the development of PU in BS patients with VC at diagnosis. Methods: The charts of 572 consecutive BS patients who were registered between 2010 and 2012 were reviewed. Among the patients with a follow-up of ≥2 years, we included 110 patients with VC in one or both eyes and 147 patients without any eye findings in both eyes at baseline and compared them for the development of PU. Results: Among the 110 included patients with VC, 61 had VC in both eyes, 34 had VC in only one eye, and 15 had VC in one eye and PU in the other eye. There was anterior uveitis (AU) in addition to VC in the same eye in 13 patients at baseline. PU developed in 24 (22%) of these patients during a mean follow-up of 1.9 ± 1.1 years. This was significantly more frequent than the 147 patients without any eye findings at baseline, among whom there were only 2 patients who developed PU (p < 0.001). Multivariate logistic regression analysis showed that having AU in addition to VC in the same eye (OR, 5.03, 95% CI; 1.37–18.47) was an independent risk factor for the development of PU in patients with VC. Conclusion: Careful follow-up is required for patients with VC at diagnosis, since 22% developed PU within 2 years.